In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1266-1269

  Briales, A ^a   Rodriguez Martinez J M ^a   Velasco, C ^a   Diaz De Alba P ^a   Dominguez Herrera J ^b   Pachon J ^b   Pascual, A ^a,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEUCINE; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ESCHERICHIA COLI; GENE EXPRESSION; GENE MUTATION; GYRA GENE; IN VITRO STUDY; NONHUMAN; PARC GENE; PRIORITY JOURNAL; QNRA1 GENE; QNRB1 GENE; QNRS1 GENE;

CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 79952341314     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00927-10     Document Type: Article

References (20)

1. Allou, N., E. Cambau, L. Massias, F. Chau, and B. Fantin. 2009. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob. Agents Chemother. 53:4292-4297.
2. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement M100-S20. CLSI, Wayne, PA.
3. de Toro, M., et al. 2010. In vivo selection of aac(6′)-Ib-cr and mutations in the gyrA gene in a clinical qnrS1-positive Salmonella enterica serovar Typhimurium DT104B strain recovered after fluoroquinolone treatment. J. Antimicrob. Chemother. 65:1945-1949.
4. Drlica, K., and X. Zhao. 2007. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44:681-688.
5. Hooper, D. C. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-341.
6. Lipman, J., J. Scribante, A. G. Gous, H. Hon, and S. Tshukutsoane. 1998. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob. Agents Chemother. 42:2235-2239.
7. Marcusson, L. L., N. Frimodt-Moller, and D. Hughes. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 5:e1000541.
8. Marcusson, L. L., S. K. Olofsson, L. P. Komp, O. Cars, and D. Hughes. 2005. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J. Antimicrob. Chemother. 55:938-943. (Pubitemid 40883179)
9. Martinez-Martinez, L., C. M. Eliecer, J. Manuel Rodriguez-Martinez, J. Calvo, and A. Pascual. 2008. Plasmid-mediated quinolone resistance. Expert Rev. Anti Infect. Ther. 6:685-711.
10. Martinez-Martinez, L., A. Pascual, I. Garcia, J. Tran, and G. A. Jacoby. 2003. Interaction of plasmid and host quinolone resistance. J. Antimicrob. Chemother. 51:1037-1039.
11. Martinez-Martinez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799.
12. Morgan-Linnell, S. K., and L. Zechiedrich. 2007. Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 51:4205-4208. (Pubitemid 350057831)
13. Poirel, L., et al. 2006. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. Antimicrob. Agents Chemother. 50:1525-1527.
14. Posfai, G., V. Kolisnychenko, Z. Bereczki, and F. R. Blattner. 1999. Markerless gene replacement in Escherichia coli stimulated by a double-strand break in the chromosome. Nucleic Acids Res. 27:4409-4415.
15. Rodriguez-Martinez, J. M., et al. 2008. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1. Clin. Microbiol. Infect. 14:691-697.
16. Rodriguez-Martinez, J. M., et al. 2007. Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob. Agents Chemother. 51:2236-2239. (Pubitemid 46903126)
17. Rodriguez-Martinez, J. M., C. Velasco, A. Pascual, I. Garcia, and L. Martinez- Martinez. 2006. Correlation of quinolone resistance levels and differences in basal and quinolone-induced expression from three qnrA-containing plasmids. Clin. Microbiol. Infect. 12:440-445.
18. Strahilevitz, J., G. A. Jacoby, D. C. Hooper, and A. Robicsek. 2009. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin. Microbiol. Rev. 22:664-689.
19. Turnidge, J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58(Suppl. 2):29-36. (Pubitemid 29500082)
20. Zhao, X., and K. Drlica. 2008. A unified anti-mutant dosing strategy. J. Antimicrob. Chemother. 62:434-436.